Effects of Hydrogen Gas Inhalation on Community-Dwelling Adults of Various Ages: A Single-Arm, Open-Label, Prospective Clinical Trial.
Md Habibur Rahman, Johny Bajgai, Subham Sharma, Eun-Sook Jeong, Seong Hoon Goh, Yeon-Gyu Jang, Cheol-Su Kim, Kyu-Jae Lee · Antioxidants (Basel, Switzerland) · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The results suggested that t-Tau and p-Tau levels were significantly reduced after 4 weeks of H₂ gas inhalation treatment, which was effective for improved neurodegenerative diseases, such as AD, which is shown in Figure 5 and Figure S4. These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 4 participants. The results suggested that t-Tau and p-Tau levels were significantly reduced after 4 weeks of H₂ gas inhalation treatment, which was effective for improved neurodegenerative diseases, such as AD, which is shown in Figure 5 and Figure S4.
What the Researchers Studied
The researchers studied 4 participants. The study used a randomized human clinical trial.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 10 µM H₂ (≈0.02 mg/L); Source-reported hydrogen exposure: 10 µM H₂ (≈0.02 mg/L); reported treatment duration: 4 weeks. The results suggested that t-Tau and p-Tau levels were significantly reduced after 4 weeks of H₂ gas inhalation treatment, which was effective for improved neurodegenerative diseases, such as AD, which is shown in Figure 5 and Figure S4. The authors concluded that H₂ gas inhalation may be a good candidate for improving AD with cognitive dysfunction in community-dwelling adults of different ages.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 4 participants. The reported sample size was 4. The study used a randomized human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 10 µM H₂ (≈0.02 mg/L). The source-reported hydrogen exposure was 10 µM H₂ (≈0.02 mg/L). The reported treatment duration was 4 weeks.
Limitations and Safety
Safety information: H₂ gas inhalation is reportedly safe and has a positive impact on a range of illnesses, including Alzheimer's disease (AD). The total and differential WBC counts were not adversely affected after H₂ gas inhalation, indicating that it was safe and well tolerated. no adverse effects were recorded after four weeks of treatment with H₂ gas inhalation, and therefore, it can be considered a safe and well-tolerated healthy supplement for the treatment of AD in community-dwelling adults of various ages.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.